<DOC>
	<DOCNO>NCT00577850</DOCNO>
	<brief_summary>The primary objective study compare urinary excretion 14C-labeled risedronate alendronate 28 day .</brief_summary>
	<brief_title>Pharmacokinetics Single 14C-labeled Dose Risedronate Alendronate Followed Once-a-week Unlabeled Oral Dose</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>medical history documentation verify postmenopausal status least 2 year ( natural surgical ) . If document , confirmation require use estradiol &lt; 20 pg/mL follicle stimulate hormone ( FSH ) &gt; 40 IU/mL ; osteopenia osteoporosis ( &lt; 1.002 g/cm2 Lunar &lt; 0.882 g/cm2 Hologic ) determine DXA lumbar spine ( AP PA view , L1L4 ) . This correspond Tscore approximately &lt; 1.5. clinically significant outofrange laboratory value vital sign , clinically significant cardiovascular , hepatic , renal , parathyroid disease , opinion Investigator know hypersensitivity bisphosphonates</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>